EP1461068A4 - Verfahren und zusammensetzungen zur normalisierung der lipidspiegel in säugergeweben - Google Patents
Verfahren und zusammensetzungen zur normalisierung der lipidspiegel in säugergewebenInfo
- Publication number
- EP1461068A4 EP1461068A4 EP02803945A EP02803945A EP1461068A4 EP 1461068 A4 EP1461068 A4 EP 1461068A4 EP 02803945 A EP02803945 A EP 02803945A EP 02803945 A EP02803945 A EP 02803945A EP 1461068 A4 EP1461068 A4 EP 1461068A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- lipid levels
- mammalian tissues
- normalizing lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33342201P | 2001-11-26 | 2001-11-26 | |
NZ51573101 | 2001-11-26 | ||
US333422P | 2001-11-26 | ||
NZ51573101 | 2001-11-26 | ||
PCT/NZ2002/000262 WO2003045424A1 (en) | 2001-11-26 | 2002-11-26 | Methods of compositions for normalizing lipid levels in mammalian tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1461068A1 EP1461068A1 (de) | 2004-09-29 |
EP1461068A4 true EP1461068A4 (de) | 2006-03-29 |
Family
ID=26652295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02803945A Withdrawn EP1461068A4 (de) | 2001-11-26 | 2002-11-26 | Verfahren und zusammensetzungen zur normalisierung der lipidspiegel in säugergeweben |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1461068A4 (de) |
JP (1) | JP2005523418A (de) |
CN (1) | CN1617737A (de) |
AU (2) | AU2002356469A1 (de) |
CA (1) | CA2471833A1 (de) |
WO (1) | WO2003045424A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324234A (zh) | 1998-09-25 | 2001-11-28 | 格利科克斯有限公司 | 果糖胺氧化酶,拮抗剂和抑制剂 |
CA2478997C (en) | 2002-03-08 | 2013-12-17 | Protemix Corporation Limited | Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure |
CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
CA2577634C (en) | 2004-07-19 | 2015-07-07 | Protemix Corporation Limited | Synthesis of triethylenetetramines |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
CN103702685B (zh) | 2011-05-20 | 2017-12-15 | 奥尔德生物控股有限责任公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途 |
JP6189832B2 (ja) | 2011-05-20 | 2017-08-30 | アルダーバイオ・ホールディングズ・エルエルシー | 慢性および急性の下痢を治療または予防するための抗cgrp若しくは抗cgrp−rの抗体または抗体断片の使用 |
US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
CA2916980C (en) * | 2013-07-03 | 2023-02-21 | Alder Biopharmaceuticals, Inc. | Regulation of glucose metabolism using anti-cgrp antibodies |
US11639380B2 (en) | 2019-01-08 | 2023-05-02 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0309100A2 (de) * | 1987-08-26 | 1989-03-29 | Amylin Pharmaceuticals, Inc. | Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus |
WO1996004928A1 (en) * | 1994-08-16 | 1996-02-22 | Human Genome Sciences, Inc. | Calcitonin gene related peptide receptor |
EP0845269A2 (de) * | 1996-11-29 | 1998-06-03 | Weihan Wo | Liposomzusammensetzung enthaltende Peptid hinsichtlich menschlichen Calcitocingenes und ihre Herstellung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
WO1994021665A1 (en) * | 1993-03-24 | 1994-09-29 | Amylin Pharmaceuticals, Inc. | Cloned receptors and methods for screening |
WO1998003534A1 (en) * | 1996-07-23 | 1998-01-29 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
EP1053001B1 (de) * | 1998-02-13 | 2010-12-15 | Amylin Pharmaceuticals, Inc. | Neue verbindungen mit gemischter amylin aktivität |
-
2002
- 2002-11-26 CA CA002471833A patent/CA2471833A1/en not_active Abandoned
- 2002-11-26 EP EP02803945A patent/EP1461068A4/de not_active Withdrawn
- 2002-11-26 CN CNA028275691A patent/CN1617737A/zh active Pending
- 2002-11-26 WO PCT/NZ2002/000262 patent/WO2003045424A1/en active Application Filing
- 2002-11-26 JP JP2003546925A patent/JP2005523418A/ja active Pending
- 2002-11-26 AU AU2002356469A patent/AU2002356469A1/en not_active Withdrawn
-
2009
- 2009-03-26 AU AU2009201147A patent/AU2009201147A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0309100A2 (de) * | 1987-08-26 | 1989-03-29 | Amylin Pharmaceuticals, Inc. | Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus |
WO1996004928A1 (en) * | 1994-08-16 | 1996-02-22 | Human Genome Sciences, Inc. | Calcitonin gene related peptide receptor |
EP0845269A2 (de) * | 1996-11-29 | 1998-06-03 | Weihan Wo | Liposomzusammensetzung enthaltende Peptid hinsichtlich menschlichen Calcitocingenes und ihre Herstellung |
Non-Patent Citations (5)
Title |
---|
CHATZIPANTELI K ET AL: "CALCITONIN GENE-RELATED PEPTIDE IS AN ADIPOSE-TISSUE NEUROPEPTIDE WITH LIPOLYTIC ACTIONS", ENDOCRINOLOGY AND METABOLISM, LONDON, GB, vol. 3, no. 4, 1996, pages 235 - 242, XP008057490, ISSN: 1074-939X * |
HETTIARACHCHI M ET AL: "Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 273, no. 5 PART 1, November 1997 (1997-11-01), pages E859 - E867, XP002362126, ISSN: 0002-9513 * |
MOORE MARY COURTNEY ET AL: "Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 48, no. 5, May 1999 (1999-05-01), pages 603 - 610, XP002362125, ISSN: 0026-0495 * |
See also references of WO03045424A1 * |
YE J-M ET AL: "EVIDENCE THAT AMYLIN STIMULATES LIPOLYSIS IN VIVO: A POSSIBLE MEDIATOR OF INDUCED INSULIN RESISTANCE", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 280, no. 4, PART 1, April 2001 (2001-04-01), pages E562 - E569, XP009009879, ISSN: 0002-9513 * |
Also Published As
Publication number | Publication date |
---|---|
AU2009201147A1 (en) | 2009-04-23 |
AU2002356469A1 (en) | 2003-06-10 |
WO2003045424A1 (en) | 2003-06-05 |
CN1617737A (zh) | 2005-05-18 |
CA2471833A1 (en) | 2003-06-05 |
JP2005523418A (ja) | 2005-08-04 |
AU2002356469A2 (en) | 2003-06-10 |
EP1461068A1 (de) | 2004-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1380207A4 (de) | Verfahren zur konservierung von säugetierorganen | |
HK1079987A1 (zh) | 使用細胞脫唾液酸決定簇和糖綴合物將細胞靶向組織和器官的方法和組合物 | |
EP1660663A4 (de) | Verfahren und zusammensetzungen zur gewebereparatur | |
HK1070830A1 (en) | Hypotensive lipid and timolol compositions and methods of using same | |
GB0325742D0 (en) | Viscoelastic compositions | |
HK1086738A1 (zh) | 使用去氧苯經妥組合物調節哺乳動物的角蛋白組織 | |
AU2003223416A1 (en) | Tissue analogs for in vitro testing and method of use therefor | |
AU2003265010A1 (en) | Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein | |
AU2001239873A1 (en) | Adjuvant treatment by in vivo activation of dendritic cells | |
AU2002359949A1 (en) | Compositions for improving lipid metabolism | |
EP1603932A4 (de) | Verfahren und zusammensetzungen für die enzymatische synthese von gangliosiden | |
EP1461068A4 (de) | Verfahren und zusammensetzungen zur normalisierung der lipidspiegel in säugergeweben | |
AU7833601A (en) | Charged lipid compositions and methods for their use | |
AU2001294820A1 (en) | Methods for in vivo reduction of free radical levels and compositions useful therefor | |
EP1381839A4 (de) | Verfahren zur bildlichen darstellung von zelltod in vivo | |
TWI367753B (en) | Composition for normalization of infradian rhythm | |
EP1469769A4 (de) | Neue zusammensetzungen und verfahren gegen krebs | |
GB0325277D0 (en) | Surgical instruments for use in the implantation of tissue repair kit | |
AU2002353078A8 (en) | Tissue graft compositions and methods for producing same | |
AU2003215264A8 (en) | Compositions and methods for delivery of skin cosmeceuticals | |
EP1469870A4 (de) | Neue zusammensetzungen und methoden bei krebs | |
AU2001255730A1 (en) | Methods and compositions for the treatment of cardiac indications | |
EP1539199A4 (de) | Verfahren und zusammensetzungen f r die in-vivo-beseitigung von erregern | |
AU2003263962A8 (en) | Tissue compositions and methods for producing same | |
EP1283727A4 (de) | Zusammensetzungen und verfahren zum induzieren von aktivierung dentritischer zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040625 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1069977 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060210 |
|
17Q | First examination report despatched |
Effective date: 20070301 |
|
19U | Interruption of proceedings before grant |
Effective date: 20100713 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTEMIX CORPORATION LIMITED |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1069977 Country of ref document: HK |
|
19W | Proceedings resumed before grant after interruption of proceedings |
Effective date: 20111004 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHILERA NEW ZEALAND LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120204 |